Is Armata Pharmaceuticals (ARMP) Stock Outpacing Its Medical Peers This Year?

Group 1 - Armata Pharmaceuticals, Inc. (ARMP) has shown strong performance in the Medical sector, returning about 60% year-to-date, significantly outperforming the sector average of -2.3% [4] - The Zacks Rank for Armata Pharmaceuticals is 2 (Buy), indicating positive analyst sentiment and a stronger earnings outlook, with a 24.7% increase in the consensus estimate for full-year earnings over the past 90 days [3] - Armata Pharmaceuticals belongs to the Medical - Biomedical and Genetics industry, which has an average gain of 3.3% this year, positioning ARMP as a better performer within this specific industry [5] Group 2 - The Medical sector includes 973 individual stocks and currently holds a Zacks Sector Rank of 6, reflecting the average strength of the sector [2] - Another stock in the Medical sector, Actinium Pharmaceuticals (ATNM), has also outperformed the sector with a year-to-date return of 27.8% and a Zacks Rank of 2 (Buy) [4][5] - The Medical - Drugs industry, where Actinium Pharmaceuticals is categorized, has 155 stocks and has moved up by 10.1% since the beginning of the year, indicating a relatively strong performance compared to the broader Medical sector [6]